Cited by

• Animal models in studies of cardiotoxicity side effects from antiblastic drugs in patients and occupational exposed workers.

  Lamberti M, Giovane G, Garzillo EM, Avino F, Feola A, Porto S, Tombolini V, Di Domenico M. Lamberti M, et al. Biomed Res Int. 2014;2014:240642. doi: 10.1155/2014/240642. Epub 2014 Feb 19. Biomed Res Int. 2014. PMID: 24701565 Free PMC article. Review.
• Correlation of HER2 codon 655 polymorphism with cardiotoxicity risk in Chinese HER2-positive breast cancer patients undergoing epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab adjuvant chemotherapy.

  Tan L, Su X, Li X, Li H, Hu B. Tan L, et al. Int J Clin Exp Pathol. 2020 Feb 1;13(2):286-294. eCollection 2020. Int J Clin Exp Pathol. 2020. PMID: 32211111 Free PMC article.
• Predictors of late-onset heart failure in breast cancer patients treated with doxorubicin.

  Qin A, Thompson CL, Silverman P. Qin A, et al. J Cancer Surviv. 2015 Jun;9(2):252-9. doi: 10.1007/s11764-014-0408-9. Epub 2014 Oct 24. J Cancer Surviv. 2015. PMID: 25342090
• Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence.

  Segovia-Mendoza M, González-González ME, Barrera D, Díaz L, García-Becerra R. Segovia-Mendoza M, et al. Am J Cancer Res. 2015 Aug 15;5(9):2531-61. eCollection 2015. Am J Cancer Res. 2015. PMID: 26609467 Free PMC article. Review.
• Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology.

  Lancellotti P, Galderisi M, Donal E, Edvardsen T, Popescu BA, Farmakis D, Filippatos G, Habib G, Lestuzzi C, Santoro C, Moonen M, Jerusalem G, Andarala M, Anker SD; ESC Cardiac Oncology Toxicity Long-Term Registry Investigators. Lancellotti P, et al. ESC Heart Fail. 2017 Aug;4(3):312-318. doi: 10.1002/ehf2.12162. Epub 2017 May 2. ESC Heart Fail. 2017. PMID: 28772051 Free PMC article.